

**VANDERBILT UNIVERSITY MEDICAL CENTER  
DIVISION OF TRAUMA AND SURGICAL CRITICAL CARE**

**Massive Transfusion Protocol**

---

---

Background: Protocolized transfusion has been shown to improve clinical outcomes as well as transfusion efficiency in patients who require massive transfusion (>10 u in 24 hours). This document provides guidelines for utilization of the massive transfusion protocol (MTP) at VUMC.

1. Patient selection
  - a. Patients with current, ongoing, or impending massive blood loss should be considered for activation of MTP.
  - b. Activation of massive transfusion protocol should be considered for patients who received greater than two units of blood in the emergency department.(1)
2. Activation
  - a. MTP may be activated by the attending surgeon, intensivist or designated surrogate. If surrogate activates MTP, attending surgeon of record must be provided to blood bank (BB).
  - b. MTP may be activated by trauma/surgical cc faculty, fellows and instructors; anesthesiology faculty; and selected surgical faculty ONLY.
  - c. Upon suspicion of MTP activation, type and screen must be sent to BB as soon as possible.
  - d. To activate MTP, call the BB at 2-2233 and provide the following information
    - i. "This is Dr. \_\_\_\_\_ activating MTP....."
    - ii. Patient name
    - iii. Patient MRN. This will be repeated by BB personnel for verification purposes.
    - iv. Patient age
    - v. Patient gender
    - vi. Current or intended location
3. Product breakdown
  - a. Each round of MTP provides 6U PRBC, 4U FFP, 1 dose pack of platelets
  - b. Repeat rounds of MTP contain identical product "doses"
4. Administration
  - a. Products are delivered, and BB calls patient location to verify continuation of MTP. Default is to continue MTP until verbally discontinued by faculty physician.
  - b. MTP boxes are intended to be given in their entirety until completed. If not all products are desired, strong consideration should be given to MTP discontinuation.
5. Endpoints/termination
  - a. When appropriate endpoints are reached, the MTP must be discontinued to limit resource utilization.
  - b. Most reliable transfusion endpoint is a collaborative decision based on operative field examination, laboratory results, and clinical parameters.
  - c. Premature discontinuation of MTP should be avoided to minimize catch-up reactive transfusion.
6. Pitfalls, common errors
  - a. Failure to send type and screen.
    - i. T&S must be sent upon suspicion of MTP requirement.
  - b. Returning platelets on ice.
    - i. Cold temperature destroys platelets. Must be returned in cooler side pouch.
  - c. Failure to identify significant hemorrhage, delayed MTP activation.
    - i. Results in delayed resuscitation. Over-activation is expected.

- d. Premature termination.
  - i. Consider continuing MTP until patient stabilizes in the ICU.
- e. Failure to provide entire box/dose.
  - i. If not all products are required, d/c MTP and transfuse PRN.
  - ii. Collaborate with intensivist/anesthesiologist regarding transfusion plan.
- f. Reliability on laboratory tests alone for transfusion indication.
  - i. Laboratory tests are unreliable in the hyperacute setting.
- g. Inappropriate personnel activating MTP.
  - i. BB personnel are empowered to refuse MTP to callers who are not authorized to activate protocol.

Contacts:

Pampee Young, MD, PhD  
Blood Bank/Laboratory Medicine

Oliver Gunter, MD  
Trauma/Critical Care

Scott Hoffman, MD  
Anesthesiology

Richard Miller, MD  
Trauma/Critical Care  
Chair of Blood Utilization Committee

1. **Nunez, T.C., Voskresensky, I.V., Dossett, L.A., Shinall, R., Dutton, W.D., and Cotton, B.A. 2009. Early prediction of massive transfusion in trauma: simple as ABC (assessment of blood consumption)? *The Journal of trauma* 66:346-352.**

*Revised 2011, Oliver L. Gunter, M.D., FACS*